CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Rosemary Harrison Joins TCR Therapeutics as Chief Business and Strategy Officer

Rosemary Harrison Joins TCR...

Clinical Research Technology Leader RealTime Secures Growth Investment from LLR Partners

Clinical Research Technology Leader...

Catalyst Biosciences Announces Major Leadership Changes

Catalyst Biosciences Announces Major...

Merakris Therapeutics Partners with Miracles In Sight Eye Bank

Merakris Therapeutics Partners with...

BetterLife- Carleton University Research Team Secures Funding form Mitacs

BetterLife- Carleton University...

ClearPoint Neuro Appoints Lynnette C. Fallon to Board of Directors

ClearPoint Neuro Appoints Lynnette C....

Marc Drimer, CPA, Joins the Board of Directors of Curative Biotechnology

Marc Drimer, CPA, Joins the Board of...

BioStem Technologies Announces the Approval of Q Code for VENDAJE from CMS

BioStem Technologies Announces the...

Rosemary Harrison Joins TCR Therapeutics as Chief Business and Strategy Officer

Rosemary Harrison Joins TCR...

Clinical Research Technology Leader RealTime Secures Growth Investment from LLR Partners

Clinical Research Technology Leader...

Catalyst Biosciences Announces Major Leadership Changes

Catalyst Biosciences Announces Major...

Merakris Therapeutics Partners with Miracles In Sight Eye Bank

Merakris Therapeutics Partners with...

BetterLife- Carleton University Research Team Secures Funding form Mitacs

BetterLife- Carleton University...

ClearPoint Neuro Appoints Lynnette C. Fallon to Board of Directors

ClearPoint Neuro Appoints Lynnette C....

Marc Drimer, CPA, Joins the Board of Directors of Curative Biotechnology

Marc Drimer, CPA, Joins the Board of...

BioStem Technologies Announces the Approval of Q Code for VENDAJE from CMS

BioStem Technologies Announces the...

James Pekarsky Joins Gelteq as Chief Financial Officer

Life Sciences Review Life Sciences Review | Tuesday, July 27, 2021
Tweet

Gelteq appoints James Pekarsky as CFO.


FREMONT, CA: Gelteq Pty Ltd, a global leader in ingestible gel technology for healthcare, nutrition, and sports, appoints James Pekarsky as the Chief Financial Officer, as the company accelerates its global launch, including its first significant entry into the United States market.


Pekarsky offers over 30 years of finance and executive experience from biotechnology and technology companies to Gelteq. This includes 15 years as CEO and CFO of publicly traded companies, five years as general manager of large US-based companies operating in Europe, and ten years as a founder and CEO of start-up companies in Silicon Valley, where he led several financings, initial public offerings, acquisitions, and exits.


Pekarsky formerly co-founded and ran BioPharmX, a NYSE-listed business focused on new pharmaceutical delivery technologies, where he led several financings and the firm's initial public offering. He has since worked as an executive consultant for private firms in the medical and high-tech sectors, advising on all aspects of finance and operations, including fundraising, mergers and acquisitions, business development, and corporate governance.


“We welcome Jim’s extensive financial knowledge and operational experience, particularly his success with developing novel pharma delivery systems,” states Simon Szewach, Gelteq co-founder and executive chairman. “His proven capabilities and knowhow greatly complement our fast-track for growth and our expanding team of industry pioneers. 


We expect Jim to play an essential role as we continue to ramp our sales and marketing, manufacturing and licensing programs on a global scale, as well as pursue opportunities in the capital markets to accelerate this growth.”


Pekarsky served as CFO of several successful semiconductor companies before co-founding BioPharmX, including Wavesat (acquired by Cavium Networks/Marvell), SiliconBlue Technologies (developed by Lattice), Mosys (a Nasdaq-listed company), AccelChip (acquired by Xilinx), and Virage Logic Corporation (acquired by Synopsis). He also oversaw Virage's Nasdaq initial public offering.


“I see tremendous market opportunities and multiple ways for Gelteq to capitalize on its extensive IP portfolio and growing number of international patents that support its innovative gel delivery system,” comments Pekarsky. “The sports, health and wellness, and pharma partnerships the company has formed are impressive and support its commercial rollout. Im looking forward to supporting the company’s continued growth and international expansion.”


Pekarsky earned a bachelor's degree in accounting from the Indiana University of Pennsylvania and a master's degree in business administration from Golden Gate University in San Francisco.


Weekly Brief

loading
> <
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue

Read Also

Role of Predictive Genomics in Sustainable Healthcare

Role of Predictive Genomics in Sustainable Healthcare

A Conversational AI Approach to Regulatory Intelligence

A Conversational AI Approach to Regulatory Intelligence

A rise in DNA Sequencing Market is expected in coming years

A rise in DNA Sequencing Market is expected in coming years

Omniabio Inc. Announces Private Investor

Omniabio Inc. Announces Private Investor
Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Lithuania's Vision to Become a Biotech Hub in Europe

Lithuania's Vision to Become a Biotech Hub in Europe

Bridging the Diversity Gap in Genomics

Bridging the Diversity Gap in Genomics

How does Biotechnology Provide Solutions to Human Needs?

How does Biotechnology Provide Solutions to Human Needs?
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/james-pekarsky-joins-gelteq-as-chief-financial-officer-nwid-467.html